Lansoprazole reduced recurrence of ulcer complications in long-term use of low-dose aspirin


**Question**
In patients receiving continuous treatment with low-dose aspirin, is *Helicobacter pylori* eradication plus lansoprazole more effective than *H. pylori* eradication alone for preventing the recurrence of ulcer complications?

**Design**
Randomized [allocation concealed]*†, blinded (clinicians, patients, outcome assessors, monitoring committee, and data analysts),* placebo-controlled trial with a median follow-up of 12 months.

**Setting**
A university hospital in Hong Kong, China.

**Patients**
123 patients who were 18 to 80 years of age (mean age 70 y, 72% men) and had ulcers (gastric, duodenal, or gastroduodenal), were receiving low-dose aspirin for > 1 month before developing ulcers, had a disease such as stroke or ischemic heart disease that required long-term continuous treatment with low-dose aspirin, and had *H. pylori* infection that was objectively diagnosed. Exclusion criteria included esophagitis; a history of gastric or duodenal surgery other than oversewing of a perforation; allergy to study drugs; *H. pylori* infection that could not be eradicated after 2 attempts with eradication therapies; and concomitant treatment with nonsteroidal anti-inflammatory drugs, corticosteroids, or anticoagulants. Follow-up was 92%.

**Intervention**
After healing of the ulcers and eradication of *H. pylori* infection, 62 patients were allocated to aspirin (100 mg/d) plus lansoprazole (30 mg/d), and 61 patients were allocated to aspirin (100 mg/d) plus placebo, all taken once daily for 12 months.

**Main Outcome Measures**
Recurrence of ulcer complications (bleeding, perforation, or obstruction).

**Main Results**
Analysis was by intention to treat. Fewer patients in the lansoprazole group than in the placebo group had a recurrence of ulcer complications (Table).

**Conclusion**
In patients receiving continuous treatment with low-dose aspirin, *Helicobacter pylori* eradication plus lansoprazole was more effective than *H. pylori* eradication alone for preventing the recurrence of ulcer complications.

**Source of funding:** The Peptic Ulcer Research Fund of the University of Hong Kong.

For correspondence: Dr. K.C. Lai, Queen Mary Hospital, Hong Kong, China. E-mail: kclai@hku.hk.

*See Glossary.
†Information provided by author.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Lansoprazole</th>
<th>Placebo</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrence of ulcer complications</td>
<td>1.6%</td>
<td>14.8%</td>
<td>89% (37 to 98)</td>
<td>8 (5 to 24)</td>
</tr>
</tbody>
</table>

†Abbreviations defined in Glossary. RRR, NNT, and CI calculated from data in article.

**Commentary**
Even low doses of aspirin can cause serious ulcer complications. *H. pylori* infection, which is a risk factor for aspirin-associated ulcers (1), is more prevalent in Hong Kong (where the study by Lai and colleagues was done) than in North America. Lai and colleagues showed that eradication of *H. pylori* infection alone was inadequate for preventing recurrence of ulcer complications in Chinese patients who were restarted on low-dose aspirin after ulcer healing. The combination of *H. pylori* eradication and subsequent maintenance with lansoprazole was substantially superior to *H. pylori* eradication alone in preventing ulcer complications within 1 year. We do not know the “natural” rate of recurrent ulcer complications without either of these interventions because the inclusion of a control group in which patients were not offered treatment for *H. pylori* infection would have been unethical.

A recent multinational study (currently only available in abstract form) found a point prevalence of endoscopic ulcers of 11% in patients who were receiving aspirin, 75 to 325 mg/d, but not nonsteroidal anti-inflammatory drugs, proton-pump inhibitors, or H2-antagonists (1).

Advancing age and *H. pylori* infection were risk factors for ulcers, while dyspepsia was a negative predictor. Therefore, some patients receiving low-dose aspirin (particularly elderly and asymptomatic persons) will have ulcers and will be at risk for complications. This does not mean that they all require long-term treatment with proton-pump inhibitors. However, those who have an ulcer complication should be tested for *H. pylori* infection, which should be treated if present. For such patients who are resuming low-dose aspirin because of a medical necessity, long-term proton-pump inhibitor co-therapy after documented ulcer healing and *H. pylori* eradication is recommended.

Colin W. Howden, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois, USA

**Reference**